Navidea Biopharmaceuticals Inc (NAVB)

[Norm]

PRESS RELEASE: Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

Chief Executive Officer to Provide Business and Development Program Updates DUBLIN, Ohio--(BUSINESS WIRE)--April 01, 2013--

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, Navidea's President and Chief Executive Officer, will participate at the Future Leaders in the Biotech Industry Conference on April 5, 2013 at the Millennium Broadway Hotel & Conference Center, New York, NY. Dr. Pykett will provide an update of the Company and its development programs at 9:30 AM EDT.

Investors and the public are invited to listen to a live webcast of Dr. Pykett's presentation at http://www.media-server.com/m/p/exttmn6v. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms -- Lymphoseek(R) , NAV4694, NAV5001 and RIGScan(TM) -- to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

CONTACT: Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr. VP & CFO

Order free Annual Report for Navidea Biopharmaceuticals, Inc.

Visit http://djnweurope.ar.wilink.com/?ticker=US63937X1037 or call [phone]

(END) Dow Jones Newswires
04-01-13 1605ET